JPRN-jRCTs051220082进行中（未招募）2 期
A multicenter, randomized controlled trial to determine the oPtimal duRation of sterOid Therapy for mild pneumonitis associated with immunE Check poinT inhibitors - PROTECT trial
Akamatsu Hiroaki0 个研究点目标入组 106 人开始时间: 2022年8月30日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 106
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Informed written consent before enrollment in the study.
- •2) At least 20 years of age at the time consent is obtained.
- •3) Drug-induced pneumonitis has been diagnosed by at least two physicians.
- •4) Drug-induced pneumonitis of Grade 1 or 2 (CTCAE ver.5.0) which developed during or after immune checkpoint inhibitor-included therapy.
- •5) More than 3 months since completion of chest radiation.
- •6) Weighing at least 30 kg.
- •7) Expected to live despite cancer for at least 12 weeks at the time of enrollment.
- •8) ECOG PS of 0-2.
- •9) Transcutaneous oxygen saturation (SpO2) >= 93% with room air at rest.
- •10) Meeting the following laboratory criteria within 8 days prior to enrollment
- •Neutrophil count >= 1000 /mm3
- •Hemoglobin >= 7.0 g/dL
- •Platelet count >= 50,000 /uL
- •Creatinine level < 3.0 mg/dl
排除标准
- •Patients who meet any of the following criteria are ineligible
- •1) Disease or condition that may interfere with their ability to understand, perform or comply with study procedures.
- •2) Active tuberculosis (latent tuberculosis is not considered active).
- •3) Have undergone surgery within 28 days prior to enrollment or are expected to require surgery within 56 days of the start of study treatment (excluding minor surgery such as drain placement or tooth extraction).
- •4) Patients who received systemic administration of corticosteroids or other immunosuppressive agents (e.g., cyclophosphamide, azathioprine, methotrexate, thalidomide, anti-TNF agents) within 14 days before enrollment.
- •Mineralocorticoids (e.g., fludrocortisone) for orthostatic hypotension, and low-dose steroid replacement for adrenocortical insufficiency are acceptable.
- •Patients who have received short-term steroids for less than one week in diseases other than pneumonitis will be considered for enrollment after consultation with the principal investigator.
- •5) Current or past autoimmune diseases with possible interstitial lung complications (inflammatory bowel disease [e.g., ulcerative colitis or Crohn's disease], systemic lupus erythematosus, dermatomyositis, scleroderma, Sjogren's syndrome, and
- •Patients with confirmed sarcoidosis, polyangitis granulomatosa, mixed connective tissue disease, vasculitis syndrome, rheumatoid arthritis, etc.). However, the following are eligible for inclusion:
- •-Patients with vitiligo or alopecia vulgaris.
- •-Patients with hypothyroidism (e.g., Hashimoto's disease) that has been stabilized by hormone replacement therapy.
- •-Chronic skin diseases that do not require systemic treatment.-Patients whose disease has not progressed rapidly within the past 5 years at the time of enrollment may be eligible for inclusion. However, this is limited to cases discussed by the Principal Investigator.
- •In the case of an autoimmune disease not listed above, the Principal Investigator will discuss the case and decide whether or not the patient can be enrolled.
- •6) History of significant cardiovascular disease (e.g., NYHA Class III or higher heart disease, myocardial infarction within the past 3 months, uncontrolled arrhythmia)
- •7) Uncontrolled pleural, ascites, or pericardial effusions
- •In case of drainage for >24 hours, it must have been at least 7 days since the drainage was stopped (drainage on the same day of the week before the registration date is acceptable), and no Grade 3 or higher fluid retention has been observed since the drainage was stopped.
- •No exacerbation after drain removal is acceptable.
- •8) Diabetes mellitus that is poorly controlled by appropriate treatment.
- •9) Patients requiring steroid therapy for purposes other than drug-induced pneumonitis (excluding replacement therapy).
- •10) Grade 3 or higher immune-related adverse events.
- •11) Otherwise deemed inappropriate for participation in the study by the treating physician.
研究者
相似试验
已完成
不适用
RESPOND—A patient-centred program to prevent secondary falls in older people presenting to the emergency department (ED) with a fall: Protocol for a multi-centre randomised controlled trialACTRN12614000336684The Falls and Bone Health Team, Health Services Research Unit, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University528
招募中
3 期
The comparison of tissue acquisition for gastrointestinal subepithelial tumors of 2 cm or less with endoscopic ultrasound-guided fine-needles: A multicenter randomized controlled trialJPRN-jRCTs052230144Kitano Masayuki110
暂停
3 期
A multicenter, randomized, controlled trial to reveal the efficacy of fully covered vs uncovered SEMS for malignant biliary obstruction caused by unresectable pancreatic cancer (confirmatory Trial)malignant biliary obstruction caused by unresectable pancreatic cancermalignant biliary obstruction, unresectable pancreatic cancerJPRN-jRCTs052210032Takenaka Mamoru300
尚未招募
1 期
A multicenter, randomized, controlled trial for a novel vaginal microecologic therapy for the treatment of persistent cervical human papillomavirus infection at high riskITMCTR2000003652Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine
进行中（未招募）
不适用
A multi-center, randomized, controlled trial with programmed introduction of Sirolimus-based, Calcineurin inhibitor free immunosuppression in recipients of non-heart-beating donor kidney grafts. - PRINS studyEUCTR2007-002763-27-NLErasmus MC